Safety, activity, and immune effects of lenalidomide and rituximab in untreated indolent lymphoma

BACKGROUND: Standard treatments for indolent non-Hodgkin lymphomas (iNHLs) are frequently toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed iNHL. The aim of this phase 2 trial (NCT00695786) was to evaluate the efficacy and...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Lancet Oncol
Κύριοι συγγραφείς: Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, Neelapu, Sattva S
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2014
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4370362/
https://ncbi.nlm.nih.gov/pubmed/25439689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70455-3
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια